AstraZeneca PLC (AZN.L) News Headlines

▮ More

Date

Headline

9/23/2022 2:36:46 AM Ionis: AstraZeneca Decides Not To Advance ION449 Into Phase 3 Based On Pre-specified Criteria

9/23/2022 2:13:55 AM AstraZeneca Announces Approval For Ultomiris By The European Commission

9/23/2022 2:04:22 AM AstraZeneca: Ultomiris Approved In Europe For Adults With Generalised Myasthenia Gravis

9/22/2022 2:18:11 AM AstraZeneca Announces Approval Of Lynparza In China

9/22/2022 2:05:43 AM AstraZeneca Says Lynparza Approved In China For Ovarian Cancer

9/21/2022 2:19:04 AM AstraZeneca: Tezspire Gets EU Approval To Treat Severe Asthma

9/21/2022 2:02:05 AM AstraZeneca Says Tezspire Approved In EU For The Treatment Of Severe Asthma

9/20/2022 2:36:52 AM AstraZeneca Says Its Antibody Combination Treatment For Covid 'Evusheld' Approved In EU

9/20/2022 2:08:42 AM AstraZeneca Says Evusheld Approved In EU For COVID-19 Treatment

9/16/2022 4:33:45 AM AstraZeneca's Phase III Trial Of Danicopan In Paroxysmal Nocturnal Haemoglobinuria Meets Goals

9/16/2022 3:21:28 AM AstraZeneca PLC Says Danicopan Phase III Trial Meets Primary Endpoint

9/16/2022 2:54:32 AM AstraZeneca's Evusheld Gets CHMP Recommendation For EU Approval To Treat COVID-19

9/16/2022 2:22:45 AM AstraZeneca: CHMP Recommends Beyfortus For EU Approval - Quick Facts

9/16/2022 2:07:59 AM AstraZeneca Says Evusheld Recommended For Marketing Authorisation In EU For The Treatment Of COVID-19

9/16/2022 2:05:25 AM AstraZeneca PLC Says Beyfortus Recommended For Approval In The EU By CHMP

9/11/2022 9:28:40 PM AZN: Enhertu Continues To Show Meaningful Tumor Response In Lung Cancer Across Phase II Trial

9/9/2022 8:58:35 AM AstraZeneca Says LYNPARZA Combination Shows Meaningful OS In Ovarian Cancer Across Phase III Trials

9/9/2022 8:04:52 AM AstraZeneca : LYNPARZA Combination Shows Meaningful Survival Benefit In Ovarian Cancer Across Phase III Trials

9/7/2022 2:59:41 AM Ionis Presents Positive Results From Phase 3 Study Of Eplontersen In Neuropathy Impairment

9/7/2022 2:33:47 AM Ionis Presents Positive Results From Phase 3 NEURO-TTRansform Study On Amyloidosis

Astrazeneca Plc (AZN.L)